Cargando…

Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial)

INTRODUCTION: The efficacy and safety of taspoglutide, a long-acting human glucagon-like peptide-1 analog, were compared with sitagliptin or placebo, as adjunct to metformin, in patients with inadequately controlled type 2 diabetes. METHODS: In this randomized, double-blind, double-dummy, parallel-g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bergenstal, Richard M., Forti, Adriana, Chiasson, Jean-Louis, Woloschak, Michael, Boldrin, Mark, Balena, Raffaella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare Communications 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508113/ https://www.ncbi.nlm.nih.gov/pubmed/23138449 http://dx.doi.org/10.1007/s13300-012-0013-8

Ejemplares similares

The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial
por: Rosenstock, Julio, et al.
Publicado: (2013)

Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of Treatment: Results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1)
por: Raz, Itamar, et al.
Publicado: (2012)

Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study1,2
por: Ratner, R, et al.
Publicado: (2010)

Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study
por: Nauck, Michael A., et al.
Publicado: (2009)

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
por: Wysham, C, et al.
Publicado: (2011)

Utilization of model-based meta-analysis to delineate the net efficacy of taspoglutide from the response of placebo in clinical trials
por: Li, Han Qing, et al.
Publicado: (2015)

Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury
por: Asakawa, Masahiro, et al.
Publicado: (2015)

Safety and Efficacy of Sitagliptin-Metformin in Fixed Combination for the Treatment of Type 2 Diabetes Mellitus
por: Ballav, Chitrabhanu, et al.
Publicado: (2013)

Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia
por: Fukuda, Masahiro, et al.
Publicado: (2018)

Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin
por: Rodbard, H. W., et al.
Publicado: (2016)

Efficacy and Safety of Sitagliptin in Japanese Patients With Type 2 Diabetes
por: Ohmura, Hirotoshi, et al.
Publicado: (2015)

Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co‐administered to Chinese patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2016)

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
por: Engel, Samuel S, et al.
Publicado: (2013)

Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
por: Arjona Ferreira, Juan Camilo, et al.
Publicado: (2013)

Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus
por: Kim, Soon Ae, et al.
Publicado: (2011)

Clinical study of repaglinide efficacy and safety in type 2 diabetes mellitus patients with blood glucose levels inadequately controlled by sitagliptin
por: Kawamori, Ryuzo, et al.
Publicado: (2015)

Pancreatic Safety of Sitagliptin in the TECOS Study
por: Buse, John B., et al.
Publicado: (2017)

Effectiveness and Safety of Sitagliptin in Patients with Beta-thalassaemia Major and Diabetes Mellitus: A Case Series
por: Zonoozi, Shahrzad, et al.
Publicado: (2017)

Efficacy and Safety of Sitagliptin for the Treatment of New-Onset Diabetes after Renal Transplantation
por: Boerner, Brian P., et al.
Publicado: (2014)

Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease
por: Sayari, Saba, et al.
Publicado: (2018)

Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START‐J trial)
por: Terauchi, Yasuo, et al.
Publicado: (2017)

Efficacy of Sitagliptin When Added to Ongoing Therapy in Korean Subjects with Type 2 Diabetes Mellitus
por: Chung, Hye Soo, et al.
Publicado: (2011)

Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes switched from glinides
por: Tanaka, Tsuyoshi, et al.
Publicado: (2013)

Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients
por: Kubota, Akira, et al.
Publicado: (2012)

Comparison of Serum Ketone Levels and Cardiometabolic Efficacy of Dapagliflozin versus Sitagliptin among Insulin-Treated Chinese Patients with Type 2 Diabetes Mellitus
por: Lee, Chi-Ho, et al.
Publicado: (2022)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
por: Miller, Shannon A, et al.
Publicado: (2009)

Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus
por: Mori, Hiroko, et al.
Publicado: (2013)

Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus()
por: Van Gaal, Luc, et al.
Publicado: (2014)

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
por: Nauck, Michael, et al.
Publicado: (2014)

Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis
por: Li, Mingxing, et al.
Publicado: (2017)

Comparative Evaluation of Safety and Efficacy of Glimepiride and Sitagliptin in Combination with Metformin in Patients with Type 2 Diabetes Mellitus: Indian Multicentric Randomized Trial - START Study
por: Devarajan, T. V., et al.
Publicado: (2017)

Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial
por: Han, Kyung‐Ah, et al.
Publicado: (2018)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

Retrospective Analysis on the Efficacy, Safety and Treatment Failure Group of Sitagliptin for Mean 10-Month Duration
por: Kim, Won Jun, et al.
Publicado: (2011)

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin
por: Kaku, Kohei, et al.
Publicado: (2021)

Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study
por: Ahmed, Ibrar, et al.
Publicado: (2022)

Pleiotropic Effects of Sitagliptin in the Treatment of Type 2 Diabetes Mellitus Patients
por: Kubota, Akira, et al.
Publicado: (2012)

Effect of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus
por: Shigematsu, Erina, et al.
Publicado: (2014)

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
por: Omoto, Seitaro, et al.
Publicado: (2015)

Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus
por: Kim, Ji Hyun
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_j2uff19qrbbq0nip1qc18ie4k7